Elicio Therapeutics is a ground-breaking brand that utilizes their innovative Amphiphile technology to engineer powerful vaccines and immunotherapies aimed at defeating aggressive forms of cancer. Combining their expertise in materials science and immunology, Elicio re-engineers the body's immune response to combat cancer and infectious diseases. Their Amphiphile platform enables the targeted delivery of immunotherapies and vaccines to the lymph nodes, where the immune response is orchestrated.

This results in tumor or pathogen-specific immunity, including robust T cell and humoral responses. Elicio's core focus lies in the development of therapeutic cancer vaccines, with their lead clinical program, ELI-002, designed to stimulate an immune response against KRAS mutations driving solid tumors. Currently undergoing Phase 1 and Phase 1/2 studies, Elicio is dedicated to revolutionizing immunotherapy and providing hope for patients battling cancer and infectious diseases